Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance
about
Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.Off-Label Use of Crizotinib as a Neoadjuvant Treatment for a Young Patient When Conventional Chemotherapy Gave No Benefits in Stage IIIA Non-Small Cell Lung Cancer.Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities.
P2860
Neoadjuvant Oncogene-Targeted Therapy in Early Stage Non-Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Neoadjuvant Oncogene-Targeted ...... Early Mechanisms of Resistance
@en
Neoadjuvant Oncogene-Targeted ...... Early Mechanisms of Resistance
@nl
type
label
Neoadjuvant Oncogene-Targeted ...... Early Mechanisms of Resistance
@en
Neoadjuvant Oncogene-Targeted ...... Early Mechanisms of Resistance
@nl
prefLabel
Neoadjuvant Oncogene-Targeted ...... Early Mechanisms of Resistance
@en
Neoadjuvant Oncogene-Targeted ...... Early Mechanisms of Resistance
@nl
P2093
P2860
P1433
P1476
Neoadjuvant Oncogene-Targeted ...... Early Mechanisms of Resistance
@en
P2093
Caroline E McCoach
Collin M Blakely
Robert C Doebele
Trever G Bivona
P2860
P304
P356
10.1016/J.CLLC.2016.05.025
P407
P577
2016-06-08T00:00:00Z